Literature DB >> 12455296

Rationale and strategies for switching antipsychotics.

Rohan Ganguli1.   

Abstract

Reasons for switching patients to different antipsychotic drugs and strategies for doing so are reviewed. Atypical antipsychotics have better adverse-effect profiles than conventional agents and may have subtle advantages in terms of efficacy. Patients who do not respond satisfactorily to one atypical antipsychotic agent may do so to another. Thus, many patients taking antipsychotic agents may benefit from a switch to another drug. However, the transition from one agent to another is itself associated with risks and uncertainties. Several switching strategies have been proposed that involve the abrupt or gradual cessation of the old drug combined with the abrupt or gradual initiation of the new drug. There are few data to suggest that one strategy is superior to another. A clinical appraisal of the conditions under which switching of drugs should occur and a careful evaluation of the appropriate strategy can help minimize the risks of switching. Planning and follow-up should include the patient, the patient's family, and social-support personnel. Guidelines for switching drugs and managing patients during the transition are being developed. When switching patients from one antipsychotic to another, good clinical judgment and a conservative approach can be used to balance the risk of clinical exacerbation with that of increased adverse effects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12455296     DOI: 10.1093/ajhp/59.suppl_8.S22

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  9 in total

Review 1.  Switching between second-generation antipsychotics: why and how?

Authors:  Monika Edlinger; Susanne Baumgartner; Nadja Eltanaihi-Furtmüller; Martina Hummer; W Wolfgang Fleischhacker
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

2.  Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy.

Authors:  Giovan B Cassano; Andrea Fagiolini; Lorenzo Lattanzi; Palmiero Monteleone; Cinzia Niolu; Emilio Sacchetti; Alberto Siracusano; Antonio Vita
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

3.  A review of pharmacologic strategies for switching to atypical antipsychotics.

Authors:  Prakash S Masand
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

Review 4.  Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review.

Authors:  Christina Mangurian; John W Newcomer; Chelsea Modlin; Dean Schillinger
Journal:  J Gen Intern Med       Date:  2016-05-05       Impact factor: 5.128

5.  Psychiatrists and neuroscientists of Indian origin in Canada: Glimpses.

Authors:  Amresh Shrivastava; D Natarajan
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

6.  Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia.

Authors:  Haya Ascher-Svanum; Alan Jm Brnabic; Anthony H Lawson; Bruce J Kinon; Virginia L Stauffer; Peter D Feldman; Katarina Kelin
Journal:  Neuropsychiatr Dis Treat       Date:  2012-03-15       Impact factor: 2.570

Review 7.  Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review.

Authors:  Benedicto Crespo-Facorro; Jose Maria Pelayo-Teran; Jacqueline Mayoral-van Son
Journal:  Neurol Ther       Date:  2016-08-23

8.  Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.

Authors:  Rohan Ganguli; Jaspreet S Brar; Ramy Mahmoud; Sally A Berry; Gahan J Pandina
Journal:  BMC Med       Date:  2008-06-30       Impact factor: 8.775

9.  The Use of Network Theory for Analyzing Switching Behaviors: Assessing Cognitive and Educational-Based Intervention for Promoting Health.

Authors:  Giorgio Gronchi
Journal:  Front Psychol       Date:  2018-06-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.